Short answer
ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
ANI PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary contained in Exhibit 99.1 press release
Item 7.01 · Regulation FD Disclosure
- Investor presentation covers third-quarter 2026 results
- Presentation addresses proposed Egetis Therapeutics acquisition
- Analyst and investor conference call and webcast held November 5, 2026
- Exhibit 99.2 provides the presentation, with materials available through investor relations:VEVENT
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $290.8M, up 27.6%, with adjusted EBITDA $83.3M, up 39.8%, signaling strong operating momentum
- Cortrophin Gel revenue $138.7M, up 36.1%, but specialty-pharmacy capacity constrained conversion from demand into treated patients
- 2026 guidance narrowed to $1,085M-$1,125M revenue and $290M-$300M adjusted EBITDA
- Cortrophin guidance reduced to $480M-$500M, while adjusted EPS guidance increased to $9.37-$9.71
- Proposed Egetis acquisition valued at approximately $560M, or $434M net of expected PRV proceeds, expanding rare-disease exposure
- Acquisition requires 90% acceptance and regulatory approvals, with financing from cash on hand and new debt
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 revenue $290.8M, up 28% YoY, with adjusted non-GAAP EBITDA $83.3M, up 40%
- Rare Disease revenue $138.7M, up 36% YoY, driven by Cortrophin Gel momentum and gout expansion
- Egetis offer values equity at SEK 5.6B, approximately $560M, with net enterprise value approximately $434M
- Financing includes existing cash and up to $300M debt, with expected post-close net leverage of approximately 2.7x
- EMCITATE offers over $300M peak-sales potential, but acquisition expected to dilute adjusted non-GAAP EPS in Year 1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANI PHARMACEUTICALS INC 8-K filings
Get the next ANIP 8-K as it lands
Follow ANIP for push alerts, or ask the research agent what this filing means.